Roche announced Phase 2 results for CT‑388 showing a placebo‑adjusted weight loss of about 22.5% at 48 weeks (22.5% excluding discontinuations; ~18.3% when counting dropouts), and said it will advance the dual GLP‑1/GIP agonist into Phase 3 testing by the end of March. Roche acquired the asset via its $2.7 billion Carmot Therapeutics deal. The company presented the mid‑stage data on Jan. 27; Jefferies and other analysts noted the efficacy is competitive with existing agents but questioned the commercial differentiation and optimal positioning against leaders like Lilly and Novo Nordisk. Roche framed CT‑388 as having “best‑in‑class potential” but acknowledged the crowded obesity market and the need for larger, longer trials. CT‑388’s mechanism—co‑stimulating GLP‑1 and GIP pathways—mirrors other late‑stage combos in obesity. Roche’s Phase 3 plan will test broader populations and dosing schemes to define durability, safety, and a path to commercial relevance.